|By ACN Newswire||
|July 9, 2014 12:34 AM EDT||
Target Asset Management Pte., Ltd, as one of the major shareholders, has hold Jintian Pharma since the IPO and steadily increases the position. According to the shareholding disclosure from HKEX on June 27, TAM invested HKD $5.1 million in order to long 2.08 million shares of Jintian Pharma (with the average price of HKD $2.45 per share).TAM's ownership is now 102 million shares or 5.09% of the issued share capital of the company. It is the first time that the ownership of Jintian has been disclosed, which also indicated that TAM feels optimistic towards the business model and the prospects of Jintian Pharmaceutical Group.
On 12 June, Jintian Pharma was authorized as the general distributor of McJayden in the Greater China Region, and on 22 June, through acquisition, Jintian Pharma became interested in the entire equity interest of Wei Kang which Jintian Pharma has held 64% equity interest in. With a series of cooperation and acquisitions, the company continues to expand its product mix and retail network, leading deeper and broader integration of pharmaceutical value chain in the PRC and attract more institutional investors.
Copyright 2014 ACN Newswire. All rights reserved.